SPEAKERS
Meet our top speakers
Antibody Speakers
Immunotherapy Speakers
Biosimilars Speakers
Gregory Adams, CSO, Elucida Oncology
Yoshiko Akamatsu, Senior Principal Research Scientist, AbbVie
Andrew Allen, President And Chief Executive Officer, Gritstone Oncology
Julian Andreev, Fellow Scientist, Regeneron
Philip Arlen, President And Chief Executive Officer, Precision Biologics Inc
Sameer Awsare, Associate Executive Director, The Permanente Medical Group Inc
Parastoo Azadi, Technical Director Of Analytical Services And Senior Research Scientist, Complex Carbohydrate Research Center
Julio Baez, Bioengineering Industrial Advisor, University of California San Diego
Christopher Bahl, Head Of Protein Design, Institute For Protein Innovation
Anita Bandrowski, Specialist, Neurosciences, UCSD
Caroline Barelle, Chief Executive Officer, Elasmogen
Dorthe Bartels, Strategic Adviser, Amgros
Abhijit Barve, Head Of Global Clinical Research And Medical Operations, Mylan Inc.
Amrik Basran, Chief Scientific Officer, Avacta Life Sciences
Dr Roy Baynes, Senior Vice President And Head Global Clinical Development, Chief Medical Officer, Merck Sharp and Dohme (MSD)
Gregory Beatty, Associate Professor, University of Pennsylvania Hospital
Laura Benjamin, Founder And Chief Executive Officer, OncXerna
Katharina Billian-Frey, Head of Protein Engineering, Apogenix AG
Zachary Bornholdt, Director, Antibody Discovery, Mapp Biopharmaceuticals
Cory Brooks, Associate Professor, California State University, Fresno
Carrie Browstein, CMO, Cellectis
Samantha Bucktrout, Senior Director of Research, Parker Institute for Cancer Immunotherapy
Mr Rob Burgess, Chief Business Officer, Sino Biological Inc
Alex Burgin, Executive Director, Institute For Protein Innovation
Iain Campuzano, Principal Scientist, Amgen Inc
Ping Cao, VP, Business Development, Shanghai Henlius Biotech, Inc
Paul Carter, Senior Director And Staff Scientist, Antibody Engineering, Genentech
Brian Champion, Chief Scientific Officer, Psioxus Therapeutics Ltd
Kartik Chandran, Associate Professor, Department Of Microbiology And Immunology, Albert Einstein College of Medicine
Melody Chang, Director of Pharmacy Operations, American Oncology Network
Youhai Chen, Professor of Pathology and Laboratory Medicine, University of Pennsylvania School Of Medicine
Guodong Chen, Scientific Director, Biologics Analytical Development & Attribute Sciences, Bristol Myers Squibb
Qiang Chen, Professor, Biodesign Institute at Arizona State University
Huabiao Chen, Medicine Instructor, Harvard Medical School
Yvonne Chen, Associate Professor, University of California, Los Angeles
Mr Sidi Chen, Assistant Professor, Yale University
Isagani Chico, Executive Director and Head of the Americas Oncology Medical Group, Covance
Timothy Chiu, Pharmacist Evidence Analyst & Strategist, Kaiser Permanente
Hyelim Cho, Immunogenicity lead, Takeda
Partha Chowdhury, Senior Director, Protein Engineering, Janssen
Sarah Cianferani-Sanglier, Senior Scientist, Institut Pluridisciplinaire Hubert Curien
Hillel Cohen, Executive Director, Scientific Affairs, Sandoz Biopharmaceuticals Gmbh
Steven Corn, Founder And Chief Executive Officer, Metis Advocacy
Christina Coughlin, Chief Medical Officer, Rubius Therapeutics
Kelly Coulbourne, Allergan
James Crowe, Director, Vanderbilt Vaccine Center
Patty Culp, Senior Director of Cell Biology and Assay Development, Maverick Therapeutics
Marc Damelin, Vice President & Head of Biology, Mersana Therapeutics, Inc.
Marianne Davies, Associate Professor, Yale School Of Nursing
Jonathan Davis, Head of Innovation, Invenra INC
Brandon DeKosky, Assistant Professor Of Pharmaceutical Chemistry And Chemical Engineering, University of Kansas
lelia delamarre, Principal Scientist, Genentech
John Delaney, Director, Research Technologies And Collaborations, Amgen Inc
Liang Deng, Associate Member, Memorial Sloan-Kettering Cancer Center
Danielle Dettling, Director, Research And Development, Maverick Therapeutics
Richard Ding, Director Of Downstream Purification And Manufacturing, AnaptysBio, Inc.
Feng Dong, Senior Scientist Iii, AbbVie
Prof Stefan Duebel, Director, Braunschweig University of Technology
Colin Edgerton, Executive Chairman, American Rheumatology Network
Peter Ellmark, VP Discovery, Alligator Bioscience AB
Lauren Ely, Senior Principle Scientist, Pfizer
Yoshua Esquenazi Levy, Neurosurgeon, Memorial Hermann Texas Medical Center
Mourad Farouk Rezk, Global Head Of Medical And Regulatory, Biosimilars, Biogen
Andrea Ferrante, Principal Research Scientist, Eli Lilly and Company
Dana Filoti, Principal Scientist I/ Head of Research and Early Development NBE Analytical R&D, AbbVie
Mr Spencer Fisk, Senior VP, Manufacturing, Rubius Therapeutics
Tiffany Fletcher, Head of Global Biosimilar Policy & Access, Mylan
John Flygare, Senior Principal Scientist, Merck And Co Inc
Alex Franzusoff, Chief Executive Officer, Pact Pharma
Agnete Fredriksen, President And Chief Scientific Officer, VACCIBODY AS
Jeffrey Froude, Director, WRAIR Pilot Bioproduction Facility, Defense Threat Reduction Agency
Joseph Fuhr, Professor Of Economics, Widener University
Rajkumar Ganesan, Director, Antibody Engineering And Bispecific, Janssen BioTherapeutics
Bernhard Geierstanger, Executive Director, Discovery Biologics, Merck
Hanspeter Gerber, Interim CEO, CSO, 3T Biosciences
Federico Gherardini, Director, Informatics, Parker Institute for Cancer Immunotherapy
Raja Ghosh, Associate Professor Of Chemical Engineering And Research Chairman, McMaster University
Ms Elizabeth Hewitt Gibson, Senior Director, Operations, California Life Sciences Association - CLSA
Sandhya Girish, VP, Clinical Pharmacology, Gilead Sciences
Mr Francisco Gonzalez, Associate Principal Scientist, Fujifilm Diosynth Biotechnologies
Sangeeta Goswami, Assistant Professor, MD Anderson Cancer Center
Parag Goyal, Director Biologics R&D, Mylan Inc
Bonnie Gunn, Assistant Professor, Washington State University
Taylor Guo, Co-Founder And Chief Scientific Officer, I-Mab Biopharma
Sanjeev Gupta, General Manager - Advanced Biotech, Ipca Laboratories: Pharmaceutical Company
eric halioua, President & CEO, PDC*line pharma SA
Trevor Hallam, Chief Scientific Officer, Sutro Biopharma
Jeonghoon Han, Vice President, Chief Development And Technology Officer, Eutilex Ltd
Brenda Hann, Director, Clinical Trials Operations, Stanford University School of Medicine
Matthew Harman, VP, Clinical Solutions, Employers Health
Ms Erin Harris, Chief Editor, Cell & Gene, Life Science Connect
Christopher R Heery, Chief Medical Officer, Precision BioSciences
Kristen Hege, Senior Vice President, Early Clinical Development, Hematology/Oncology and Cell Therapy, Bristol-Myers Squibb
Kevin Henry, Research Officer, National Research Council Canada
Inmaculada Hernandez, Assistant Professor (Pharmacy and Therapeutics), University of Pittsburgh
Tim Hickling, Head of Immunosafety, Roche
Lawrence Hill, Chief Executive Officer, Gan & Lee Pharmaceuticals USA
Soraya Hölper, Lab Head Mass Spectrometry, Sanofi - Biologics Research
Yue Huang, Scientist II, AstraZeneca
Li Hui, Scientific director, Biocytogen
Elizabeth Jex, Attorney Advisor, FTC
Jennifer Jung, Lab Head Mass Spectrometry, Sanofi
Maria Karasarides, Vice-President, Head Early Assets & Biomarkers, Bristol-Myers Squibb
Balveen Kaur, Professor And Vice Chair Research, The University of Texas Health Science Center at Houston
Rahul Kaushik, Vice President and Head of Antibody/Protein Process Development and Manufacturing, FibroGen Inc
Dr Hans S Keirstead, Chief Executive Officer, AIVITA Biomedical, Inc.
Bruce Keyt, CSO, IgM. Biosciences Inc
Payal Khandelwal, Head of Product Management, Protein Analysis, Sartorius
Deepak Khatry, Lead, Clinical Trials Biostatistics, Westat
Philip Kim, Associate Professor, University of Toronto
Kyung-Ah Kim, Vice President, Samsung Bioepis
Leonid Kirkovsky, Director, Pfizer
Vadim Klyushnichenko, Vice President Of Pharmaceutical Development And Quality, Calibr, a division of Scripps Research
Kevin Knopf, Chairman Hematology And Oncology, Highland Hospital
Karin Koch, University Lab Partners
David Korn, Vice President, Intellectual Property and Law, phrma
Giedre Krenciute, Assistant Member, St. Jude Children's Research Hospital
Dr. Rajesh Krishnan, Chief Technology Officer, Oncternal Therapeutics
Stanley Krystek, Research Fellow, Bristol-Myers Squibb
Daniel Lafkas, Scientist, Genentech
Jonathan Lai, Professor of Biochemistry, Albert Einstein College of Medicine
Hun Lee, Global Leader of Protein Design, Synbio Technologies
Dr James Legg, Vice President, Research And Development, Crescendo Biologics Ltd
Steve Lehrer, Managing Director, SBLehrer LLC
Bruce Leicher, Strategic Legal Advisor and Adjunct Professor in Biotechnology Law, University of New Hampshire
Hy Levitsky, President of Research & Development, Century Therapeutics
Nathan Lewis, Associate Professor, Department Of Pediatrics And Bioengineering,, University of California San Diego
Ming Li, Assistant Professor, Memorial Sloan-Kettering Cancer Center
Tony Liu, CEO & CFO, Cellular Biomedicine Group, Inc
David Liu, Instructor In Medicine, Dana Farber Cancer Institute
Cate Lockhart, Executive Director, Biologics and Biosimilars Collective Intelligence Consortium
Angelica Loskog, Chief Executive Officer, Lokon Pharma
Mark Lowdell, Chief Scientific Officer, Inmunebio
Lawrence Lum, Professor Of Oncology, University Of Virginia
Geoffrey Lynn, Chief Executive Officer and Co-Founder, Avidea Technologies
Maria-Céu Machado, Vice President, Federation of European Academies of Medicine
Julie Marechal-Jamil, Biosimilars Policy & Science, Medicines for Europe
Peter Marks, Director, Center For Biologics Evaluation And Research (CBER), U.S. Food and Drug Administration
Pierre Martineau, Team leader, IRCM & Scientific Advisor, Mabqi
Marc Martinez-Llordella, Founder, Vice President Biology, Quell Therapeutics
Ivan Mascanfroni, Director of Immunology, Pandion Therapeutics
Ali McBride, Clinical Coordinator, University Of Arizona
Werner Meier, Chief Scientific Officer, Revitope Oncology, Inc.
Ira Mellman, Vice President, Cancer Immunology, Genentech
Jeffrey Miller, Deputy Director, University of Minnesota
John Misasi, Staff Clinician, NIH
Si Mou, Scientist I, AstraZeneca
Liviu Movileanu, Professor, Department Of Physics, Syracuse University
Ruipeng Mu, Senior Scientist, AstraZeneca
Patricia Odermatt, Single B cell Scientist, Genovac
Ted Okon, Executive Director, Community Oncology Alliance
Sofia Oliveira Martins, Professor, University of Lisbon
Sonia Oskouei, VP, Biosimilars, Cardinal Health
Kathy Oubre, COO, Pontchartrain Cancer Center
Rachel Overman, JPM CBRN Medical
Mr Lauri Peil, Key Account And Technology Officer, Icosagen Cell Factory OU
Samanthi Perera, Associate Principal Scientist, Quantitative Biosciences, Merck
Edith Perez, Chief Medical Officer, Bolt Biotherapeutics
Joann Peters, VP Clinical & Business Operations, Geneos Therapeutics
Elizabeth Pham, Scientist, Oncology, Amgen
Dr Laurent Poirot, SVP Immunology, Cellectis SA
Ned Pojskic, Leader, Pharmacy And Health Provider Relations, Greenshield Insurance Brokers LLC
Mr Robert Popovian, Vice President Of Government Relations, Pfizer
David L Porter, Director, Cell Therapy And Transplantation, University of Pennsylvania
Matthew Porteus, Associate Director, Definitive And Curative Medicine, stanford university
Mark Poznansky, Director, Vaccine And Immunotherapy Center, Massachusetts General Hospital
Nina Prak, Professor of Pathology and Laboratory Medicine, Perelman School of Medicine University of Pennsylvania
James Purcell, Program Director, Oncology Discovery, AbbVie
Ellen Pure, Professor and Chair, Department of Biomedical Sciences, University of Pennsylvania School of Veterinary Medicine
Kamal Puri, CSO, Oncoresponse, Inc.
Yu Qiu, Principal scientist, Sanofi
David Quach, Instructor, Baylor College of Medicine
Maryam Raeeszadeh-Sarmazdeh, Assistant Professor of Chemical Engineering, University of Nevada
Jack A Ragheb, Senior Medical Fellow Of Immunology, Eli Lilly and Company
Eva Rahman Kabir, Professor, Brac University
Sundar Ramanan, Vice President, Head, Global Regulatory Affairs, Biocon Pharmaceuticals
Dr Vasu Rangadass, President & CEO, L7 Informatics
Romesh Rao, Research Associate, Seattle Genetics Inc
David Raulet, Lab Head, Faculty Director, Immunotherapeutics and Vaccine Research Initiative, UC Berkeley
Janice Reichert, Executive Director, The Antibody Society
Anton Rosenbaum, Head of Regulated Bioanalysis and OMICS by LC-MS, AstraZeneca
Dr Rafael Rosengarten, CEO, Genialis, Inc
Theodore Roth, Managing Director And Phd Student, University of California, San Francisco
Brandon Ruotolo, Professor Of Chemistry, University of Michigan
Jack Sadowsky, Scientist, Genentech
Yardena Samuels, Professor, Weizmann Institute
Erica Ollmann Saphire, Professor, La Jolla Institute for Allergy and Immunology
Mr Aaron Sato, Chief Scientific Officer of Twist Biopharma, Twist Bioscience
Karsten Sauer, VP, Repertoire Immune Medicines
Hans Sauer, Vice President For Intellectual Property, Biotechnology Innovation Organization
Philip Schneider, Advisory Board Chair, Alliance for Safe Biologic Medicines
Stephen Schoenberger, Professor, La Jolla Institute for Allergy and Immunology
Shawn Scranton, Chief Operating Officer and Senior Vice President of Late Stage Development, Pfenex
Rebecca Sendak, Head of the Global Large Molecules Research Platform, Sanofi
Dr Alessandro Sette, Center Head, Division Head, And Professor,, La Jolla Infectious Disease Institute
bhavesh shah, director of pharmacy, boston medical center
Lu Shan, Associate Director, Antibody Engineering, Denali Therapeutics
Susan Sharfstein, Associate Professor, S.U.N.Y. Polytechnic Institute
Joan Shen, Head Of Research And Development, I-Mab Biopharma
Christine M Simmon, Executive Director, Biosimilars Council
Anupam Singhal, Sr. Product Manager, Antibody Discovery, Berkeley Lights
Will Singleterry, Commercial Director – Immuno-Oncology, LUMICKS
Jeffrey Skolnik, Senior Vice President Of Clinical Development, Inovio Pharmaceuticals
Alan Smith, Executive Vice President, Technical Operations, Bellicum Pharmaceuticals
Mariana Socal, Assistant Scientist, Johns Hopkins University
Peggy Sotiropoulou, Head of R&D, Celyad Oncology
Jamie Spangler, Assistant Professor, John Hopkins University
Matthew Spear, Chief Medical Officer, Poseida Therapeutics, Inc.
Ryan Stafford, Sr Director, Antibody Engineering, Immune-Onc Therapeutics
Gary Starling, Associate Vice President, Discovery Biologics, Merck
Graham Statt, Assistant Deputy Minister Of Alberta Health, Pharmaceutical And Supplementary Benefits And Vice Chair, The pan-Canadian Pharmaceutical Alliance
Blaine Stine, Director, Global Biologics Discovery, AbbVie
Mr Pawel Stocki, Reseach Director, Ossianix, Inc.
Mr Lars Stockl, Senior Director Buisness Development, FyoniBio – Service Branch of Glycotope
Sebastian Stolzenberg, Postdoctoral Project Leader, Freie University of Berlin
Noelle Sunstrom, Chief Executive Officer, NeuClone
Anish Suri, Chief Scientific Officer, Cue Biopharma
Sean Taylor, Field Application Scientist Manager, North America, GenScript
Eva Temkin, Acting Director for Policy, Office of Therapeutic Biologics and Biosimilars, FDA
Paul Thomas, Chief Commercial Officer, US; Biocon Biologics, Biocon Biologics
Nathan Trinklein, Chief Technology Officer, Teneobio
Al Tsang, Chief Scientific Officer, Precision Biologics Inc
Andrew Urick, Senior Scientist, AbbVie
Dr Bob Valamehr, Chief Development Officer, Fate Therapeutics
Bernhard Valldorf, Lab Head Biologics Formulation Development, Merck Healthcare KGaA
John Valliere Douglass, Associate Director, Seattle Genetics Inc
Sjoerd Van Der Burg, Professor Of Experimental Cancer Immunology And Therapy, Leiden University Medical Center
Marit van Gils, Associate Professor, Amsterdam UMC
Ms Christine Vannais, Chief Operating Officer, FUJIFILM Diosynth Biotechnologies
Feng Wang, Associate Director, Bristol-Myers Squibb
Yunan Wang, Scientist, Amgen Inc
Maria Wendt, Head of Biologics Research US & Global Head Digital Biologics Platform (ML/AI), Sanofi
Timothy Whitehead, Associate Professor, University of Colorado
Nancy Whiting, Senior Vice President, Development, Seattle Genetics Inc
Christopher Williamson, Senior Research Scientist, AbCellera
Laura Wingate, Senior Vice President of Education, Support and Advocacy, Crohn's and Colitis Foundation
Farrah Wong, Senior Director, Commercial Formulary And Contracting Strategy, Optumrx
David Wraith, Director, Institute of Immunology and Immunotherapy, University of Birmingham
Han Xiao, Assistant Professor, Chemistry Biosciences And Bioengineering, Rice University
Michael Xie, Executive Director of Bioassay and Analytical Development, Shanghai Henlius Biotech
Sarah Yim, Director, Ofc of Ther Biol. & Biosim., FDA
Peter Yingxiao Wang, Professor Of Bioengineering, UCSD
Yu Zhang, SVP & CSO, Vcanbio Cell And Gene Engineering
Eugene Zhukovsky, CSO, BIOMUNEX PHARMACEUTICALS
Stefan Zielonka, Associate Director, Protein Engineering And Antibody Technologies, Merck KGaA
Adam Zwolak, Principal Scientist, Janssen Research & Development
Contact us
To sponsor or exhibit contact:
Derek Cavanagh
+44 (0)207 092 1297
derek.cavanagh@terrapinn.com
To speak:
Natasha Evans
+44 (0)207 092 1212
Natasha.Evans@terrapinn.com
Organiser
